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OBJECTIVE — To investigate if long-acting insulin analogs decrease the risk of diabetic
ketoacidosis (DKA) in young individuals with type 1 diabetes.
RESEARCH DESIGN AND METHODS — Of 48,110 type 1 diabetic patients prospec-
tively studied between 2001 and 2008, the incidence of DKA requiring hospitalization was
analyzed in 10,682 individuals aged 20 years with a diabetes duration of 2 years.
RESULTS — The overall rate of DKA was 5.1 (SE  0.2)/100 patient-years. Patients using
insulinglargineordetemir(n5,317)hadahigherDKAincidencethanindividualsusingNPH
insulin(n5,365,6.60.4vs.3.60.3,P0.001).TheriskforDKAremainedsigniﬁcantly
differentafteradjustmentforageatdiabetesonset,diabetesduration,A1C,insulindose,sex,and
migration background (P  0.015, odds ratio 1.357 [1.062–1.734]).
CONCLUSIONS — Despite their long-acting pharmacokinetics, the use of insulin glargine
or detemir is not associated with a lower incidence of DKA compared with NPH insulin.
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L
ipolysis and ketogenesis leading to
diabetic ketoacidosis (DKA) may be
suppressed by the continuous provi-
sionofsmalldosesofinsulin(1,2).DKAis
frequently caused by omission of insulin
injections,observedin28–65%ofyoung
patients with type 1 diabetes (3,4). In
youngchildren,theuseofinsulinglargine
and detemir was associated with a trend
to less DKA episodes compared with
NPH/zinc insulin (5), potentially related
to the prolonged action of these insulin
analogs (6–8). We hypothesized that
long-acting insulin analogs may confer
greaterprotectionfromDKAinyoungpa-
tients with type 1 diabetes.
RESEARCH DESIGN AND
METHODS— Based on the Diabetes
Prospective Documentation (DPV) Initia-
tive (9), a study was performed to evalu-
ate the incidence of DKA in patients with
type 1 diabetes using either NPH insulin
or long-acting basal insulin analogs. A to-
talof48,110patientswithtype1diabetes
were consecutively registered between
2001 and 2008 at 271 diabetes centers in
Germany and Austria, with an estimated
nationwide capture rate of 80%.
Subjects aged 20 years with diabe-
tesduration2yearsusingthreeormore
insulin injections daily without change of
type of long-acting insulin during the last
18 months were included into the study.
Insulin therapy was not modiﬁed for
study purposes. DKA was deﬁned as ve-
nousbloodpH7.3andtherequirement
ofhospitaltreatment.DKAincidencedur-
ing the recent 12 treatment months was
assessed.LocallymeasuredA1Cwasstan-
dardized to the Diabetes Control and
Complications Trial (DCCT) reference
range of 4.05–6.05% using the multiple
of the mean method.
Statistical analyses were performed
using SAS software (SAS version 9.1; SAS
Institute, Cary, NC). Nonparametric
(Kruskal-Wallis)or
2statisticswereused
for comparison among groups followed
by the Holm adjustment (Bonferroni
step-down) for multiple comparisons. P
values 0.05 were considered statisti-
cally signiﬁcant. Odds ratios (OR) derived
from multiple logistic regression analysis
were listed as point estimates and 95%
Wald CI.
RESULTS— Of 48,110 eligible pa-
tients with type 1 diabetes, 26,639 indi-
viduals were aged 20 years with a
diabetes duration of 2 years. Subjects
withcontinuoussubcutaneousinsulinin-
jections (n  4,553), change in basal in-
sulin during the last 18 months (n 
9,334), less than three injections per day
or no documented basal insulin (n 
1,053), missing documentation of insulin
therapy (n  792), or the use of zinc in-
termediate-acting insulin (n  225) were
excluded. In effect, 10,682 individuals
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were included in the analysis.
Clinical characteristics of patients us-
ing long-acting basal insulin analogs (n 
5,317) or NPH insulin (n  5,365) are
summarized in Table 1. The overall num-
berofDKAeventsintheentirecohortwas
549duringtherecenttreatmentyear,cor-
responding to a DKA incidence of 5.14 
0.22 (SE/100 patient-years).
Patients using long-acting insulin an-
alogs had higher DKA risk than patients
with NPH insulin (Table 1). Multiple lo-
gistic regression analysis with adjustment
forA1C,diabetesduration,ageatdiabetes
onset, sex, migration background, insu-
lin therapy (dose of short-acting insulin
analogs, daily insulin dose, prandial/
basal ratio), and treatment year con-
ﬁrmed higher DKA risk in the long-
acting insulin analog group compared
withtheNPHinsulingroup(P  0.015,
OR 1.357 [95% CI 1.062–1.734]).
Independent variables associated
with higher DKA risk were higher insulin
dose (P  0.001) and higher A1C level
(P  0.001). However, dose of short-
actinginsulinanalogs,insulinratio(pran-
dial/basal), age at diabetes onset, diabetes
duration,sex,migrationbackground,and
treatment year were not signiﬁcantly as-
sociated with DKA risk.
In patients with poor metabolic con-
trol (A1C 9.0%, n  2,652), DKA inci-
dencewas13.70.72/100patient-years.
In these patients, 63% used basal insulin
analogs.Treatmentwithlong-actinginsu-
lin analogs was associated with higher
DKA risk compared with NPH insulin
(P  0.003, OR 1.639 [95% CI 1.180–
2.277]) in this subgroup of patients.
When DKA risk was separately ana-
lyzed for insulin glargine or detemir ver-
susNPH,theassociationwithhigherDKA
risk was conﬁrmed for both long-acting
insulin analogs (P  0.035, OR 1.268
[95% CI 0.978–1.643] and 1.526
[1.092–2.133]). In patients with poor
metabolic control, even higher DKA inci-
dences associated with insulin glargine or
detemir compared with NPH were found
(P0.011,OR1.470[1.046–2.065]and
1.906 [1.226–2.963]).
CONCLUSIONS— The use of long-
acting insulin analogs was not associated
with a lower DKA incidence in our study
population, representing 80% of pedi-
atric patients with type 1 diabetes of 2
years’ duration in Germany and Austria.
In this cohort of 10,682 individuals, we
found 5.14 DKA events/100 patient-
years, similar to previous observations
(10). Patients using long-acting insulin
analogs had higher DKA incidence than
individuals using NPH insulin. In a pre-
vious smaller study, a nonsigniﬁcant
trend of less DKA episodes was described
in children injecting long-acting insulin
analogs (5), but mean patient age (6.5
years) and overall DKA risk were lower in
thatseries,whichmayaccountforthedif-
ferences to our ﬁndings.
Our results were derived from an ob-
servational nonrandomized prospective
study. In the study population, patients
injectinglong-actinginsulinanalogswere
older, had poorer metabolic control, and
more frequently used short-acting insu-
lins than those injecting NPH—all factors
potentially increasing DKA risk. How-
ever, after adjusting for these factors,
higher DKA risk in patients with long-
acting insulin analogs persisted, suggest-
ing that observed differences are indeed
related to insulin therapy. A variety of ad-
ditional factors may inﬂuence the risk of
DKAintype1diabeticpatients,including
treatment adherence, socioeconomic sta-
tus, infections, or residual -cell function
(3,10,11).Inourpopulation-basedstudy,
these variables could not be separately as-
sessed.DKAisfrequentlycausedbyomis-
sion of particularly the long-acting
component of a basal-bolus insulin regi-
men (10,11). Missing a once-daily injec-
tion of a long-acting insulin analog may
potentially contribute to a greater DKA
riskthanmissingoneoftwoorthreeNPH
injections.
In conclusion, despite their long-
acting pharmacokinetic proﬁle, the use of
long-acting insulin analogs was not asso-
ciated with a lower incidence of DKA
compared with NPH insulin. The possi-
bility of increased DKA risk in pediatric
patients injecting insulin glargine or det-
emir warrants further attention.
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